|
|
Profile
|
Delegates :
Yo Amakusa |
|
Incorporated :
February 1 , 2018 |
Paid in Capital :
10 Million yen |
Employees :
5 members |
Address :
Nagoya University Incubation facility102 1, Fro-cho, Nagoya-shi AICHI
〒464-0814
|
TEL/FAX :
+81-52-753-8654 / +81-52-753-8654 |
URL：
https://www.ibody.co.jp/home-english |
Attachment :
 Ojima-Kato_et_al.,_Sci._Rep,_7,_13979_(2017).pdf [ 1.6MiB ] |
Mission/Background :
iBody Inc. is a startup from Nagoya University, Japan.
We will contribute to the improvement of human health and QOL by developing new antibody therapeutics using our unique technology "Ecobody " that can discover natural human antibodies from the human body.
iBody is working on discovering and developing novel antibody therapeutics focusing on cancers, autoimmune diseases, and infectious diseases in which human antibodies play an important role in disease progression and suppression through collaborative research with academic partners.
iBody provides the service of exploring antibodies in humans and rabbits for research and diagnostics as well. |
|
Technology & Business
|
Platform Technology (Ecobody):
Ecobody enables exhaustive and rapid monoclonal antibody discovery and evaluation from single B cells without using living cells via a cell-free protein synthesis system. iBody has received exclusive license of related patents from Nagoya university.
Pipeline:
iBody is working on discovering and developing novel antibody therapeutics for solid cancers through collaborative research with academic partners.
IBC-001: Drug development project by obtaining autoantibodies of patients from tumor infiltration B cells
IBC-002: Drug development project by obtaining autoantibodies of patients against antigens specifically
expressed in multiple type of cancers
IBC-003: Drug development project by obtaining autoantibodies of patients from tumor infiltration B cells
Antibody exploring service:
iBody provides the service of exploring antibodies in humans and rabbits for research and diagnostics.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
IBC-001
|
Discovery
|
Drug development project by obtaining autoantibodies of patients from tumor infiltration B cells
|
Target identification, Conduct in vivo study
|
IBC-002
|
Discovery
|
Drug development project by obtaining autoantibodies against specific cancer antigen
|
Confirm antibody affinity against antigen, Conduct in vitro efficacy study
|
IBC-003
|
Preclinical
|
Drug development project by obtaining autoantibodies of patients from tumor infiltration B cells
|
Obtain promising antibody candidates
|
Antibody exploring service
|
Service/Marketing
|
Service of exploring antibodies in humans and rabbits for research and diagnostics
|
Receive orders from clients
|
|
|
|
|
|
Highlights
|
Drug discovery and development
IBC-001：Identified several ADC candidates effective to cancer cells.
IBC-002：Project started in mid 2020. Identified promising antibody candidates.
IBC-003：Project started in late 2020.
Platform Technology (Ecobody)
2 related patents registered in early 2020
Patent No: 6681625 Title of invention： Protein expression method
Patent No: 6744670 Title of invention： Antibody with tags
|
|
Alliance strategy
|
Drug discovery and development
・R&D collaboration on IBC-001 and IBC002
・Licensing IBC-001 and IBC002 products
・Strategic collaboration based on Ecobody technology
・Licensing Ecobody technology
Antibody exploring service:
Receiving order of exploring antibodies in humans and rabbits
|
|
|